LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | XMD11-85h | 3.33 | uM | LJP6 | 3 | P20 | 72 | hr | 2543 | 4791 | 5578 | 0.8588 | 0.7405 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 1 | M02 | 72 | hr | 2543 | 3308 | 5578 | 0.5930 | 0.2519 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 2 | M02 | 72 | hr | 2543 | 3180 | 5578 | 0.5700 | 0.2097 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 3 | M02 | 72 | hr | 2543 | 3448 | 5578 | 0.6181 | 0.2980 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 1 | O08 | 72 | hr | 2543 | 4712 | 5578 | 0.8447 | 0.7145 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 2 | O08 | 72 | hr | 2543 | 5305 | 5578 | 0.9509 | 0.9098 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 3 | O08 | 72 | hr | 2543 | 4666 | 5578 | 0.8364 | 0.6993 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 1 | J20 | 72 | hr | 2543 | 2658 | 5578 | 0.4765 | 0.0377 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 2 | J20 | 72 | hr | 2543 | 2761 | 5578 | 0.4949 | 0.0717 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 3 | J20 | 72 | hr | 2543 | 2794 | 5578 | 0.5008 | 0.0825 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 2543 | 2227 | 5578 | 0.3992 | -0.1043 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 2543 | 2372 | 5578 | 0.4252 | -0.0565 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 2543 | 2188 | 5578 | 0.3922 | -0.1171 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 1 | P14 | 72 | hr | 2543 | 4894 | 5578 | 0.8773 | 0.7744 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 2 | P14 | 72 | hr | 2543 | 4923 | 5578 | 0.8825 | 0.7840 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 3 | P14 | 72 | hr | 2543 | 5730 | 5578 | 1.0271 | 1.0499 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 1 | H02 | 72 | hr | 2543 | 1213 | 5578 | 0.2174 | -0.4383 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 2 | H02 | 72 | hr | 2543 | 1411 | 5578 | 0.2529 | -0.3731 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 3 | H02 | 72 | hr | 2543 | 1221 | 5578 | 0.2189 | -0.4357 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 1 | L20 | 72 | hr | 2543 | 2171 | 5578 | 0.3892 | -0.1227 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 2 | L20 | 72 | hr | 2543 | 2243 | 5578 | 0.4021 | -0.0990 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 3 | L20 | 72 | hr | 2543 | 2354 | 5578 | 0.4220 | -0.0624 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 1 | H08 | 72 | hr | 2543 | 1834 | 5578 | 0.3288 | -0.2337 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 2 | H08 | 72 | hr | 2543 | 1807 | 5578 | 0.3239 | -0.2426 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 3 | H08 | 72 | hr | 2543 | 1724 | 5578 | 0.3090 | -0.2700 |